Connects-UK launches to foster scientific collaborations between EU and UK researchers in a post-Brexit era
10 April 2024
Connects-UK, a new pan-European network dedicated to advancing scientific collaborations between researchers in the European Union (EU) and the United Kingdom (UK), was officially launched at an event in London yesterday. The network, led by a diaspora of EU researchers working in the UK, seeks to bridge the gap created by Brexit and ensure that collaboration, innovative research, funding, and knowledge exchange continue to thrive in the post-Brexit era.
Oxford-ZEISS Centre of Excellence officially opened
23 February 2024
ZEISS is partnering with the University of Oxford bringing ground-breaking microscopy imaging equipment, and analysis tools, to advance the study of global health and disease.
Kennedy Trust gift to help drive forward research into inflammatory and musculoskeletal diseases at Oxford
30 November 2023
Two professorships in translational medicine have been endowed at the Kennedy Institute of Rheumatology thanks to a generous gift from the Kennedy Trust for Rheumatology Research.
New PI will study the mechanical forces impacting cell fate decision-making and tissue dynamics in inflammatory diseases
23 November 2023
We welcome Adrien Hallou who has joined the Kennedy Institute as a new Principal Investigator. Adrien will be establishing his lab to better understand the role of mechanical forces on cell fate decisions and tissue dynamics in inflammatory diseases, with a particular focus on inflammatory skin diseases such as psoriasis or atopic dermatitis.
Michael Dustin joins strategic research collaboration with EvolveImmune Therapeutics
15 June 2023
The research will use the Kennedy’s state-of-the-art technology to understand the effect of EVOLVE molecules in the immune response to tumours.
New partnership will accelerate AI-driven immunotherapies
17 May 2023
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies
Two prestigious Hunterian Professorships awarded to NDORMS researchers
1 December 2022
Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England
A new research computing platform advances the understanding of key biological processes in disease
22 November 2022
To respond to advances in technology and try to answer an increasing range of biological questions, the Kennedy Institute has invested in a high-performance computing facility. We speak to Brian Marsden, Associate Professor of Research Informatics at the Kennedy to find out more.
Kennedy programmes support early career researchers
22 July 2022
Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.
Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases
5 July 2022
A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.
Yoshi Itoh wins the International Dupuytren Award 2022
30 June 2022
Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.
Professor Fiona Powrie recognised in Queen’s Birthday Honours
6 June 2022
Professor Fiona Powrie was honoured in the 2022 Queen’s Birthday Honours List, published as Her Majesty celebrates her Platinum Jubilee.
Wellcome Trust Investigator Award for Professor Arnon
12 April 2022
Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”
New Oxford-Zeiss Centre of Excellence opens at the University of Oxford
17 December 2021
The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.
The Kennedy Institute Student Symposium returns for its 5th year
30 September 2021
A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.
Researchers from the Kennedy Institute awarded MRC funding
29 September 2021
Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.
The Kennedy Institute completes its roof extension
17 August 2021
Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.
Major ERC funding awarded to Professor Michael Dustin
4 May 2021
Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.
Drug may boost vaccine responses in older adults
18 December 2020
A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults
£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships
10 December 2020
Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.